logo

PPBT

Purple Biotech·NASDAQ
--
--(--)
--
--(--)
4.64 / 10
Netural

PPBT's fundamental analysis yields a score of 4.64/10, reflecting a modest profile. Key strengths include a healthy inventory turnover ratio (47.88) and solid interest-coverage (15.51), which support operational efficiency and debt sustainability. However, negative asset-to-market value (-0.507) and revenue-to-market value (-0.264) ratios temper enthusiasm, hinting at possible overvaluation or asset-light risk. Overall, the fundamentals are balanced but not compelling, warranting cautious positioning.

Fundamental(4.64)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.26
Score3/3
Weight22.79%
1M Return11.03%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight1.47%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-1.90%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight18.29%
1M Return8.99%
PB-ROE
Value-1.01
Score3/3
Weight26.32%
1M Return13.65%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-1.97%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.17%
1M Return0.10%
Asset-MV
Value-0.51
Score1/3
Weight18.83%
1M Return8.68%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight-1.56%
1M Return-0.98%
Cash-MV
Value-0.07
Score2/3
Weight17.56%
1M Return8.80%
Is PPBT fundamentally strong?
  • PPBT scores 4.64/10 on fundamentals and holds a Fair valuation at present. Backed by its -8.64% ROE, 0.00% net margin, -2.08 P/E ratio, 0.17 P/B ratio, and 99.14% earnings growth, these metrics solidify its Netural investment rating.